|drug3771||brief mindfulness based intervention Wiki||1.00|
There is one clinical trial.
our aim is to evaluate the effectiveness of virtual brief mindfulness based interventions on psychological wellbeing, resiliency, and anxiety of frontline HCP to cope for (COVID19) stressors
Description: assessed using the (state trait anxiety-7 Item Scale); ranged from 10-40, higher score indicate more anxietyMeasure: reduction of anxiety symptom severity Time: 14 days
Description: assessed using the (Connor-Davidson Resilience Scale (CD-RISC)); score from 0-40, higher scores indicate more resilienceMeasure: change in the level of psychological resilience Time: 14 days
Description: assessed by World Health Organization wellbeing scale; changed to percent score, the higher the better.Measure: mental wellbeing Time: 14days
Description: 12-Item Short Form surveyMeasure: and functional status Time: 14 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports